Treprostinil is a medication used to treat pulmonary hypertension. Suppliers of treprostinil market it in the form of an inhalable solution, injectable solution as well as immediate-release and extended-release oral tablets. It was first introduced into medical use in 2002 by the developer and earliest manufacturer of the drug United Therapeutics Company under the trade name Remodulin. Currently, it is approved in over 40 countries, including Australia, Taiwan, Japan, and across many EU countries. United Therapeutics Company also markets treprostinil under the trade names Orenitram and Tyvaso. The three drugs together account for around 90 percent of the total treprostinil market share, with remodulin being the most popular medication of the three. A generic version of the drug from Novartis is also available on the market. Treprostinil is a very expensive medication. While 20ml (1mg/ml) of the treprostinil injectable solution is priced at around 2,500 EUR, the equivalent amount of the 2,5mg/ml solution costs 5,400 EUR to 5,600 EUR, and the 5mg/ml solution can cost from 10,000 EUR to 12,000 EUR.